Bridgebio Pharma Inc holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 338,405 | $11,698,661 | 0.02% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2025 |
| June 30, 2025 | 318,287 | $13,743,633 | 0.02% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 12, 2025 |
| Sept. 30, 2025 | 331,302 | $17,207,826 | 0.02% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 12, 2025 |
| Dec. 31, 2025 | 279,067 | $21,345,835 | 0.03% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 17, 2026 |
| March 31, 2026 | 254,392 | $18,891,150 | 0.03% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 13, 2026 |
| June 30, 2026 | Absent this quarter | — | — | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.